Intravitreous ranibizumab for persistent macular edema in retinal vein occlusion unresponsive to bevacizumab

Jennifer E. De Niro, Arthur D. Fu, Robert N. Johnson, H. Richard McDonald, J. Michael Jumper, Emmett Cunningham, Brandon Lujan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To report successful treatment of persistent retinal edema associated with retinal vascular occlusion with ranibizumab after initial failure with bevacizumab intravitreal injections. Methods: A retrospective chart review of all patients undergoing treatment with intravitreal bevacizumab for retinal vascular occlusion was undertaken. Clinical features of patients who were switched to monthly ranibizumab because of persistent and/or worsening retinal edema despite multiple (six or more) monthly intravitreal bevacizumab injections were selected for review. The type of retinal vascular occlusion, age of the patient, visual acuity at each visit, number of intravitreal bevacizumab injections, optical coherence tomography findings at each visit, fluorescein angiography, and number of intravitreal ranibizumab injections with optical coherence tomography findings at each subsequent visit were recorded. Results: Six patients (five women and one man) were identified. Age ranged from 56 years to 74 years. Five had central retinal vein occlusion and one a branch retinal vein occlusion. All were treated with at least 6 sequential intravitreal bevacizumab injections (range, 6-13) before treatment with ranibizumab. All demonstrated an immediate and marked reduction in retinal edema that had not occurred with any of the previous treatments. The average central foveal thickness on optical coherence tomography was 592 mm before ranibizumab injection and 346 mm after the injection. Visual acuity improved in four of the six patients and was stable in the remaining two patients. Conclusion: Eyes of patients with persistent macular edema secondary to retinal vein occlusion despite bevacizumab may experience prompt improvement after initiation of intravitreal ranibizumab injections.

Original languageEnglish (US)
Pages (from-to)220-224
Number of pages5
JournalRetinal Cases and Brief Reports
Volume7
Issue number3
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Retinal Vein Occlusion
Intravitreal Injections
Macular Edema
Retinal Vessels
Papilledema
Optical Coherence Tomography
Visual Acuity
Patient Acuity
Retinal Vein
Injections
Fluorescein Angiography
Therapeutics
Ranibizumab
Bevacizumab

Keywords

  • Bevacizumab
  • Ranibizumab
  • Retinal vein occlusion

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Intravitreous ranibizumab for persistent macular edema in retinal vein occlusion unresponsive to bevacizumab. / De Niro, Jennifer E.; Fu, Arthur D.; Johnson, Robert N.; McDonald, H. Richard; Jumper, J. Michael; Cunningham, Emmett; Lujan, Brandon.

In: Retinal Cases and Brief Reports, Vol. 7, No. 3, 06.2013, p. 220-224.

Research output: Contribution to journalArticle

De Niro, Jennifer E. ; Fu, Arthur D. ; Johnson, Robert N. ; McDonald, H. Richard ; Jumper, J. Michael ; Cunningham, Emmett ; Lujan, Brandon. / Intravitreous ranibizumab for persistent macular edema in retinal vein occlusion unresponsive to bevacizumab. In: Retinal Cases and Brief Reports. 2013 ; Vol. 7, No. 3. pp. 220-224.
@article{ff778135f068429889467e753454d0e7,
title = "Intravitreous ranibizumab for persistent macular edema in retinal vein occlusion unresponsive to bevacizumab",
abstract = "Purpose: To report successful treatment of persistent retinal edema associated with retinal vascular occlusion with ranibizumab after initial failure with bevacizumab intravitreal injections. Methods: A retrospective chart review of all patients undergoing treatment with intravitreal bevacizumab for retinal vascular occlusion was undertaken. Clinical features of patients who were switched to monthly ranibizumab because of persistent and/or worsening retinal edema despite multiple (six or more) monthly intravitreal bevacizumab injections were selected for review. The type of retinal vascular occlusion, age of the patient, visual acuity at each visit, number of intravitreal bevacizumab injections, optical coherence tomography findings at each visit, fluorescein angiography, and number of intravitreal ranibizumab injections with optical coherence tomography findings at each subsequent visit were recorded. Results: Six patients (five women and one man) were identified. Age ranged from 56 years to 74 years. Five had central retinal vein occlusion and one a branch retinal vein occlusion. All were treated with at least 6 sequential intravitreal bevacizumab injections (range, 6-13) before treatment with ranibizumab. All demonstrated an immediate and marked reduction in retinal edema that had not occurred with any of the previous treatments. The average central foveal thickness on optical coherence tomography was 592 mm before ranibizumab injection and 346 mm after the injection. Visual acuity improved in four of the six patients and was stable in the remaining two patients. Conclusion: Eyes of patients with persistent macular edema secondary to retinal vein occlusion despite bevacizumab may experience prompt improvement after initiation of intravitreal ranibizumab injections.",
keywords = "Bevacizumab, Ranibizumab, Retinal vein occlusion",
author = "{De Niro}, {Jennifer E.} and Fu, {Arthur D.} and Johnson, {Robert N.} and McDonald, {H. Richard} and Jumper, {J. Michael} and Emmett Cunningham and Brandon Lujan",
year = "2013",
month = "6",
doi = "10.1097/ICB.0b013e31828993b3",
language = "English (US)",
volume = "7",
pages = "220--224",
journal = "Retinal Cases and Brief Reports",
issn = "1935-1089",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Intravitreous ranibizumab for persistent macular edema in retinal vein occlusion unresponsive to bevacizumab

AU - De Niro, Jennifer E.

AU - Fu, Arthur D.

AU - Johnson, Robert N.

AU - McDonald, H. Richard

AU - Jumper, J. Michael

AU - Cunningham, Emmett

AU - Lujan, Brandon

PY - 2013/6

Y1 - 2013/6

N2 - Purpose: To report successful treatment of persistent retinal edema associated with retinal vascular occlusion with ranibizumab after initial failure with bevacizumab intravitreal injections. Methods: A retrospective chart review of all patients undergoing treatment with intravitreal bevacizumab for retinal vascular occlusion was undertaken. Clinical features of patients who were switched to monthly ranibizumab because of persistent and/or worsening retinal edema despite multiple (six or more) monthly intravitreal bevacizumab injections were selected for review. The type of retinal vascular occlusion, age of the patient, visual acuity at each visit, number of intravitreal bevacizumab injections, optical coherence tomography findings at each visit, fluorescein angiography, and number of intravitreal ranibizumab injections with optical coherence tomography findings at each subsequent visit were recorded. Results: Six patients (five women and one man) were identified. Age ranged from 56 years to 74 years. Five had central retinal vein occlusion and one a branch retinal vein occlusion. All were treated with at least 6 sequential intravitreal bevacizumab injections (range, 6-13) before treatment with ranibizumab. All demonstrated an immediate and marked reduction in retinal edema that had not occurred with any of the previous treatments. The average central foveal thickness on optical coherence tomography was 592 mm before ranibizumab injection and 346 mm after the injection. Visual acuity improved in four of the six patients and was stable in the remaining two patients. Conclusion: Eyes of patients with persistent macular edema secondary to retinal vein occlusion despite bevacizumab may experience prompt improvement after initiation of intravitreal ranibizumab injections.

AB - Purpose: To report successful treatment of persistent retinal edema associated with retinal vascular occlusion with ranibizumab after initial failure with bevacizumab intravitreal injections. Methods: A retrospective chart review of all patients undergoing treatment with intravitreal bevacizumab for retinal vascular occlusion was undertaken. Clinical features of patients who were switched to monthly ranibizumab because of persistent and/or worsening retinal edema despite multiple (six or more) monthly intravitreal bevacizumab injections were selected for review. The type of retinal vascular occlusion, age of the patient, visual acuity at each visit, number of intravitreal bevacizumab injections, optical coherence tomography findings at each visit, fluorescein angiography, and number of intravitreal ranibizumab injections with optical coherence tomography findings at each subsequent visit were recorded. Results: Six patients (five women and one man) were identified. Age ranged from 56 years to 74 years. Five had central retinal vein occlusion and one a branch retinal vein occlusion. All were treated with at least 6 sequential intravitreal bevacizumab injections (range, 6-13) before treatment with ranibizumab. All demonstrated an immediate and marked reduction in retinal edema that had not occurred with any of the previous treatments. The average central foveal thickness on optical coherence tomography was 592 mm before ranibizumab injection and 346 mm after the injection. Visual acuity improved in four of the six patients and was stable in the remaining two patients. Conclusion: Eyes of patients with persistent macular edema secondary to retinal vein occlusion despite bevacizumab may experience prompt improvement after initiation of intravitreal ranibizumab injections.

KW - Bevacizumab

KW - Ranibizumab

KW - Retinal vein occlusion

UR - http://www.scopus.com/inward/record.url?scp=84887856971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887856971&partnerID=8YFLogxK

U2 - 10.1097/ICB.0b013e31828993b3

DO - 10.1097/ICB.0b013e31828993b3

M3 - Article

VL - 7

SP - 220

EP - 224

JO - Retinal Cases and Brief Reports

JF - Retinal Cases and Brief Reports

SN - 1935-1089

IS - 3

ER -